Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

16.00
+1.339.03%
Volume:11.22M
Turnover:175.62M
Market Cap:18.33B
PE:-11.03
High:16.04
Open:14.68
Low:14.67
Close:14.67
Loading ...

Humira Holds Firm at 72% Market Share--AbbVie Fends Off Biosimilar Surge

GuruFocus.com
·
17 Jan

Samsung Bioepis Partners with Teva Pharmaceutical for Blood Disease Drug Biosimilar EPYSQLI in the US

MT Newswires Live
·
14 Jan

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

Zacks
·
14 Jan

Teva Pharmaceutical’s Growth Potential and Strategic Market Positioning

TIPRANKS
·
13 Jan

Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment

MT Newswires Live
·
13 Jan

Teva Pharmaceutical, Samsung Bioepis to Commercialize Epysqli in US

MT Newswires Live
·
10 Jan

Investing in Teva Pharmaceutical Industries (NYSE:TEVA) three years ago would have delivered you a 138% gain

Simply Wall St.
·
10 Jan

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

Zacks
·
10 Jan

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

Benzinga
·
10 Jan

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

Zacks
·
09 Jan

Catalyst Pharmaceuticals Reaches Settlement Deal With Teva Over Firdapse Patent Litigation

MT Newswires Live
·
09 Jan

Catalyst Pharmaceuticals in Settlement With Teva of Firdapse Patent Litigation

Dow Jones
·
09 Jan

BRIEF-Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE (Amifampridine) Patent Litigation With Teva Pharmaceuticals

Reuters
·
09 Jan

Catalyst Pharmaceuticals Announces Settlement of Firdapse® (Amifampridine) Patent Litigation With Teva Pharmaceuticals

THOMSON REUTERS
·
09 Jan

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

GlobeNewswire
·
09 Jan

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug

Benzinga
·
06 Jan